Wish to keep on prime of the science and politics driving biotech at this time? Join to get our biotech publication in your inbox.
Good morning. I used to be having a effective day yesterday till my colleague shared this recreation that assessments how good (or how unhealthy in my case) your colour notion is.
The necessity-to-know this morning
Vertex Pharma reported first-quarter earnings that typically matched consensus, though the corporate stated it was shelving an early stage, mRNA-based remedy for cystic fibrosis on account of poor tolerability. The drug, referred to as VX-522, was being developed as a part of a collaboration with Moderna.
Pfizer and Alkermes additionally reported earnings.
Viridian Therapeutics introduced constructive top-line outcomes from a Section 3 examine of its drug, referred to as elegrobart, in sufferers with power thyroid eye illness.
Cytokinetics drug Myqorzo meets twin efficacy targets in examine of genetic coronary heart illness
Cytokinetics stated its drug Myqorzo considerably improved coronary heart failure signs and cardiovascular health in sufferers with non-obstructive hypertrophic cardiomyopathy, an inherited coronary heart dysfunction.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
